Penumbra (PEN)

Healthcare · Medical Devices
$317.05 -0.02% on the day Market cap $12.6B 52-week range $221.26 to $362.41 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
22% a year for 10 years

At a market value of $12.6B, Penumbra's free cash flow of $175M (fiscal 2025) would need to grow about 22% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 8 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Penumbra's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price21.9% a year
Free cash flow, last 8 years140.0% a year
Revenue, same period20.4% a year
Price to free cash flow72.2x

Fundamental grade

C

Five factors scored 1 to 9 from PEN's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation1
Profitability7
Growth2
Financial health8
Cash efficiency7

Key numbers

P/E (trailing)73.9x
P/E (forward)63.4x
Price / free cash flow72.2x
EV / EBITDA56.2x
Price / sales8.39x
Price / book8.56x
Revenue growth+14.9%
Operating margin12.4%
Net margin10.7%
Return on equity10.5%
Dividend yield—
Debt / equity0.29x

Results from SEC filings

Fiscal years, from Penumbra's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$748M$847M$1.1B$1.2B$1.4B
Net income$5M-$2M$91M$14M$178M
Free cash flow-$12M-$75M$82M$147M$175M
EPS (diluted)$0.14-$0.05$2.32$0.36$4.52
Operating margin-1.0%0.72%6.9%0.78%13.5%

Where the revenue comes from

Revenue by products, fiscal 2025.

Thrombectomy$948M68%
Embolization and Other$456M32%

Superinvestors who own PEN

From each investor's latest 13F filing (what a 13F shows). 4 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Andrew Redleaf
Whitebox Advisors
Added $160M4.6%Q2 2026
Joel Greenblatt
Gotham Asset Management
Added $10M0.02%Q2 2026
Cliff Asness
AQR Capital Management
Trimmed $10M0.00%Q2 2026
PRIMECAP Management
PRIMECAP Management Co
Trimmed $8M0.00%Q2 2026

Insider buying

Open-market purchases by Penumbra's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of PEN in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when PEN trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Penumbra's stock price imply?

At a market value of $12.6B, Penumbra would need its free cash flow to grow about 22% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 8 years its free cash flow grew 140% a year.

Are Penumbra insiders buying the stock?

No open-market insider purchases of PEN in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Penumbra?

4 of the superinvestors Investingly tracks hold PEN in their latest 13F, including Andrew Redleaf, Joel Greenblatt, Cliff Asness.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.